These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21900920)

  • 1. Anticancer effects of imatinib via immunostimulation.
    Zitvogel L; Kroemer G
    Nat Med; 2011 Sep; 17(9):1050-1. PubMed ID: 21900920
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.
    Balachandran VP; Cavnar MJ; Zeng S; Bamboat ZM; Ocuin LM; Obaid H; Sorenson EC; Popow R; Ariyan C; Rossi F; Besmer P; Guo T; Antonescu CR; Taguchi T; Yuan J; Wolchok JD; Allison JP; DeMatteo RP
    Nat Med; 2011 Aug; 17(9):1094-100. PubMed ID: 21873989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role for the proapoptotic factor BIM in mediating imatinib-induced apoptosis in a c-KIT-dependent gastrointestinal stromal tumor cell line.
    Gordon PM; Fisher DE
    J Biol Chem; 2010 May; 285(19):14109-14. PubMed ID: 20231287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
    Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
    J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
    Liu Y; Tseng M; Perdreau SA; Rossi F; Antonescu C; Besmer P; Fletcher JA; Duensing S; Duensing A
    Cancer Res; 2007 Mar; 67(6):2685-92. PubMed ID: 17363589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic implications of autophagy-mediated cell survival in gastrointestinal stromal tumor after treatment with imatinib mesylate.
    Rubin BP; Debnath J
    Autophagy; 2010 Nov; 6(8):1190-1. PubMed ID: 20930540
    [No Abstract]   [Full Text] [Related]  

  • 7. Early effects of imatinib mesylate on the expression of insulin-like growth factor binding protein-3 and positron emission tomography in patients with gastrointestinal stromal tumor.
    Trent JC; Ramdas L; Dupart J; Hunt K; Macapinlac H; Taylor E; Hu L; Salvado A; Abbruzzese JL; Pollock R; Benjamin RS; Zhang W
    Cancer; 2006 Oct; 107(8):1898-908. PubMed ID: 16986125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer: Oncogenes in context.
    Heinrich MC; Corless CL
    Nature; 2010 Oct; 467(7317):796-7. PubMed ID: 20944735
    [No Abstract]   [Full Text] [Related]  

  • 9. Imatinib resistance in gastrointestinal stromal tumors.
    Chen LL; Sabripour M; Andtbacka RH; Patel SR; Feig BW; Macapinlac HA; Choi H; Wu EF; Frazier ML; Benjamin RS
    Curr Oncol Rep; 2005 Jul; 7(4):293-9. PubMed ID: 15946589
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.
    Rink L; Ochs MF; Zhou Y; von Mehren M; Godwin AK
    PLoS One; 2013; 8(1):e54477. PubMed ID: 23372733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical management of gastrointestinal stromal tumors].
    Landi B; Lecomte T; Berger A; Cellier C
    Gastroenterol Clin Biol; 2004 Oct; 28(10 Pt 1):893-901. PubMed ID: 15523227
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors.
    van Dongen M; Savage ND; Jordanova ES; Briaire-de Bruijn IH; Walburg KV; Ottenhoff TH; Hogendoorn PC; van der Burg SH; Gelderblom H; van Hall T
    Int J Cancer; 2010 Aug; 127(4):899-909. PubMed ID: 20013807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
    Corless CL; Schroeder A; Griffith D; Town A; McGreevey L; Harrell P; Shiraga S; Bainbridge T; Morich J; Heinrich MC
    J Clin Oncol; 2005 Aug; 23(23):5357-64. PubMed ID: 15928335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 15. Transporter pumps and imatinib: a cause of pharmacokinetic resistance?
    Klumpen HJ; Liddle C; Gurney H
    Cancer Biol Ther; 2008 Mar; 7(3):416-8. PubMed ID: 18334863
    [No Abstract]   [Full Text] [Related]  

  • 16. Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells.
    Curti A; Trabanelli S; Onofri C; Aluigi M; Salvestrini V; Ocadlikova D; Evangelisti C; Rutella S; De Cristofaro R; Ottaviani E; Baccarani M; Lemoli RM
    Haematologica; 2010 Dec; 95(12):2022-30. PubMed ID: 20801903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploiting antitumor immunity to overcome relapse and improve remission duration.
    Chen LL; Chen X; Choi H; Sang H; Chen LC; Zhang H; Gouw L; Andtbacka RH; Chan BK; Rodesch CK; Jimenez A; Cano P; Jones KA; Oyedeji CO; Martins T; Hill HR; Schumacher J; Willmore C; Scaife CL; Ward JH; Morton K; Randall RL; Lazar AJ; Patel S; Trent JC; Frazier ML; Lin P; Jensen P; Benjamin RS
    Cancer Immunol Immunother; 2012 Jul; 61(7):1113-24. PubMed ID: 22198309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate inhibits antigen-specific memory CD8 T cell responses in vivo.
    Sinai P; Berg RE; Haynie JM; Egorin MJ; Ilaria RL; Forman J
    J Immunol; 2007 Feb; 178(4):2028-37. PubMed ID: 17277106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro.
    Dupart JJ; Trent JC; Lee HY; Hess KR; Godwin AK; Taguchi T; Zhang W
    Mol Cancer; 2009 Nov; 8():99. PubMed ID: 19903356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.